N-dehydroxyzileuton: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10104880 |
| CHEMBL ID | 58196 |
| CHEBI ID | 173632 |
| SCHEMBL ID | 9502722 |
| MeSH ID | M0256017 |
| Synonym |
|---|
| 171370-49-3 |
| dehydroxyzyleuton |
| CHEBI:173632 |
| 1-(1-benzothiophen-2-yl)ethylurea |
| CHEMBL58196 |
| SCHEMBL9502722 |
| a-66193 |
| [1-(1-benzothiophen-2-yl)ethyl]urea |
| 1-(1-(benzo[b]thiophen-2-yl)ethyl)urea |
| unii-xt4ju9pdn5 |
| n-(1-benzo-[b]thien-2-ylethyl)urea |
| n-(1-benzo-[b]thien-2-ylethyl)urea; (1-benzo[b]thien-2-ylethyl)-urea; a 66193; abbott 66193; n-dehydroxyzileuton; zileuton related compound a |
| n-dehydroxyzileuton |
| urea, (1-benzo(b)thien-2-ylethyl)- |
| XT4JU9PDN5 , |
| abbott-66193 |
| abbott 66193 |
| n-(1-benzo(b)thien-2-ylethyl) urea |
| n-(1-benzo(b)thien-2-ylethyl)urea |
| urea, n-(1-benzo(b)thien-2-ylethyl)- |
| WGA37049 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Trough zileuton plasma concentrations (Cmin) immediately before the morning dose were higher than Cmin immediately before the afternoon dose, suggesting a diurnal variation in the pharmacokinetics of zileuton." | ( Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Witt, G, 1995) | 0.29 |
| " The pharmacokinetics of the N-dehydroxylated metabolite of zileuton were highly variable, with a more than dose-proportional increase in the mean dose-normalised Cmax and area under the concentration-time curve from zero to 24 hours." | ( The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Awni, WM; Cavanaugh, JH; Dubé, LM; el-Shourbagy, T; Locke, CS; Wong, SL, 1995) | 0.29 |
| "The diurnal variation in the pharmacokinetic parameters of zileuton were evaluated in 12 healthy male volunteers in a three-period study." | ( Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. Awni, WM; Cavanaugh, JH; Dube, LM; Locke, C, 1997) | 0.3 |
| Class | Description |
|---|---|
| 1-benzothiophenes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID7168 | Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13 | Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (50.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||